Apogee Therapeutics Inc

APGE is in a Stage 2 advancing uptrend with a steep parabolic acceleration. Currently, price is retracing toward the rising 9/21 EMA confluence after an extended rally, presenting a shallow entry opportunity. Despite overbought RSI and elevated Options Score, our momentum-oriented strategy supports buying the pullback, while acknowledging Stage 3 transition risk if EMAs fail on this retracement.

• ↑AbbVie to acquire at $135.11, 53% premium secures direct cash return.
• ↑247% 1-year gain to $133.88 52-week high highlights strong momentum.
• ↓Negative earnings yield and poor profitability underscore weak margins.